Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

13.58USD
17 Apr 2014
Price Change (% chg)

$-0.27 (-1.95%)
Prev Close
$13.85
Open
$13.72
Day's High
$14.25
Day's Low
$13.31
Volume
282,815
Avg. Vol
406,837
52-wk High
$19.25
52-wk Low
$4.46

VNDA.OQ

Chart for VNDA.OQ

About

Vanda Pharmaceuticals Inc. (Vanda) is a biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of central nervous system disorders. The Company’s product portfolio includes tasimelteon, a compound for the treatment of circadian rhythm sleep disorders (CRSD), which... (more)

Overall

Beta: 7.79
Market Cap (Mil.): $459.91
Shares Outstanding (Mil.): 33.87
Dividend: --
Yield (%): --

Financials

  VNDA.OQ Industry Sector
P/E (TTM): -- 25.58 33.33
EPS (TTM): -0.66 -- --
ROI: -18.96 -2.92 18.94
ROE: -74.98 -12.23 19.69
Search Stocks

UPDATE 2-U.S. FDA approves Vanda's circadian rhythm drug Hetlioz

Jan 31 - Vanda Pharmaceuticals Inc said on Friday that U.S. health regulators have approved its drug Hetlioz to regulate the internal body clocks of blind patients and help normalize sleep patterns.

31 Jan 2014

U.S. FDA approves Vanda's circadian rhythm drug Hetlioz

- Vanda Pharmaceuticals Inc said on Friday that U.S. health regulators have approved its experimental drug to regulate the internal body clocks of blind patients and help normalize sleep patterns.

31 Jan 2014

FDA panel backs Vanda's circadian rhythm drug

- An advisory panel to the Food and Drug Administration said on Thursday that an experimental drug designed to help regulate the internal body clocks of blind patients appears safe and effective.

14 Nov 2013

UPDATE 1-U.S. FDA panel backs Vanda's circadian rhythm drug

Nov 14 - An advisory panel to the U.S. Food and Drug Administration said on Thursday that an experimental drug designed to help regulate the internal body clocks of blind patients appears safe and effective.

14 Nov 2013

U.S. FDA review supports Vanda sleep drug; shares surge

- An experimental sleep-disorder drug made by Vanda Pharmaceuticals Inc is safe and effective enough to warrant approval, a U.S. Food and Drug Administration review found, sending the company's stock up as much as 88 percent on Tuesday.

12 Nov 2013

UPDATE 2-U.S. FDA review supports Vanda sleep drug; shares surge

Nov 12 - An experimental sleep-disorder drug made by Vanda Pharmaceuticals Inc is safe and effective enough to warrant approval, a U.S. Food and Drug Administration review found, sending the company's stock up as much as 88 percent on Tuesday.

12 Nov 2013

U.S. FDA review supports Vanda's sleep disorder drug

Nov 12 - An experimental sleep disorder drug made by Vanda Pharmaceuticals Inc is safe and effective enough to warrant approval, a U.S. Food and Drug Administration review found.

12 Nov 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Pechala's Reports
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks